SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Duramed (DRMD) Synthetic Estrogen Product
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: art slott who wrote (571)1/12/1998 6:08:00 AM
From: vestor   of 1837
 
A research analyst, I believe at Merrill, came out with the evaluation. He estimated 50 million in revenue based on approx 100 million in sales on the brand name. His reasoning was that DRMD was permitted to make a dosage that is unavailable any where else and is very much sought after by the medical community. That is why he believes DRMD would capture more market share that would otherwise be deemed expected. Would you have information on the other drugs DRMD has in its pipeline to the FDA ?
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News